Pricing Log in Create free account
Saturday 7 November 2026 Export GERN’s income statement to Excel — free account

Geron Corporation

GERN Healthcare Biotechnology

Geron Corporation’s revenue for fiscal 2025 (year ended December 2025) was $183.9 million, up 138.8% from fiscal 2024.

Revenue
+27.5%
EPS
+106.7%
Free cash flow
+176.1%
Total debt
+0.99%

Quarter to September 2026, against a year earlier

0.98 0.03 +3.16%
Market cap
$610.4M
P/E
0.0×
Fwd P/E
−20.3×
Dividend yield
—
F-score
3/9
Altman Z
−2.24
Beneish M
−1.70
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.02
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 — — — — — — — — —
Insider Ownership 5.80%

Capital & Financial Ratios $m

Size
Market Cap 610.41
Revenue ttm 217.52
Net income ttm (47.83)
Free cash flow ttm (91.16)
Net debt Q (167.93)
Valuation
P/E 0.00
Forward P/E (20.30) (negative: loss-making)
Price / sales 3.03
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.91
Financial health
Current ratio Q 6.31 (at or above 1.5: strong)
Debt / equity Q 0.53
Interest coverage Q 0.80
Growth
Revenue growth Q +27.45% (above 0%: growing)
Operating income growth Q +141.76% (above 0%: growing)
EPS, this year +83.08% (at or above 15%: strong)
EPS, next year A +463.64% (at or above 15%: strong)
Revenue, next year A +28.02% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +5.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.6×, against a ten-year median of 199×; over the ten years it ranged from 2.3× in 2026 to 6,879× in 2024.
P/S against its own 10 years 0.26%
10-year low 10-year high
P/B against its own 10 years 36.11%
10-year low 10-year high
EV/Sales against its own 10 years 0.26%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 335 408 360 288
Receivables 2 39 39 48
Inventory — 39 117 127
Other — — — —
341 491 520 469
2023 2024 2025 Q'26
Payables 6 9 11 15
ST’ Debt 47 — — —
Other — 20 17 23
108 88 112 74

Compound Annual Growth %

10y 5y 3y
Sales 17.59% 273.49% 575.71%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 4.74% 1.38% 41.34%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.01 Actual 0.00

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.03 −0.03 Met by 0.00
Q1 FY26 −0.03 −0.01 Beat by 0.02
Q2 FY26 −0.01 −0.02 Miss by 0.01
Q3 FY26 −0.01 0.00 Beat by 0.01
Q4 FY26 −0.01 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.01) (0.02) 0.00 — —
’25 (0.03) (0.02) (0.03) (0.05) (0.13)
’24 (0.09) (0.10) (0.04) (0.04) (0.27)
’23 (0.07) (0.09) (0.08) (0.09) (0.32)
’22 (0.09) (0.07) (0.10) (0.10) (0.37)
’21 (0.09) (0.09) (0.08) (0.10) (0.35)
’20 (0.08) (0.06) (0.06) (0.07) (0.28)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 52 57 60 — —
’25 40 49 47 48 184
’24 0 1 28 48 77
’23 0 0 0 0 0
’22 0 0 0 0 1
’21 0 0 0 1 1
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (63) (16) 10 — —
’25 (48) (27) (14) (22) (111)
’24 (62) (53) (59) (44) (219)
’23 (46) (30) (51) (41) (168)
’22 (34) (29) (30) (35) (127)
’21 (33) (18) (23) (22) (96)
’20 (26) (12) (15) (13) (67)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (63) (16) 10 — —
’25 (48) (28) (13) (22) (111)
’24 (63) (54) (59) (44) (219)
’23 (47) (30) (51) (41) (169)
’22 (34) (29) (30) (35) (128)
’21 (33) (18) (23) (22) (96)
’20 (26) (13) (15) (13) (67)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 6 1 1 0 0 1 1 0 77 184 218 +45.8% 235 341 525 +41.9%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 98.37 97.42 91.59 (2.6) pt
EBT (30) (28) (27) (69) (76) (116) (142) (184) (175) (83) (48) +12.2%
EBT margin, % (479.34) (2,621.22) (2,534.43) (14,901.74) (29,888.14) (8,335.39) (23,808.89) (77,690.72) (226.73) (45.41) (21.99) +433.9 pt
Net income (30) (28) (27) (69) (76) (116) (142) (184) (175) (83) (48) +12.2%
Per share, $
Per share, $ Revenue 0.04 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.12 0.28 0.32 +24.4%
Earnings (0.19) (0.18) (0.15) (0.36) (0.28) (0.35) (0.37) (0.32) (0.27) (0.13) (0.07) (4.1%)
Cash flow (0.12) (0.13) (0.12) (0.23) (0.25) (0.29) (0.33) (0.29) (0.34) (0.17) (0.13) +4.2%
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 (11.5%)
Free cash flow (0.12) (0.13) (0.12) (0.23) (0.25) (0.29) (0.34) (0.30) (0.34) (0.17) (0.14) +4.1%
Book value 0.77 0.65 1.01 0.71 0.78 0.39 0.21 0.43 0.43 0.34 0.34 (8.7%)
Shares, m 159 159 177 190 271 328 381 571 646 667 670 +17.3%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 54.98 270.61 165.58 562.21 1,706.02 286.94 1,533.36 5,152.66 29.70 4.79 3.03 976.7
P/B 2.77 2.78 0.99 1.91 2.05 3.16 11.42 4.93 8.16 3.90 2.91 4.2
EV/Sales 36.30 181.45 12.15 264.30 1,027.29 191.21 1,328.74 4,085.70 26.87 3.87 2.59 715.8
EV/FCF (12.15) (9.38) (0.62) (2.75) (3.88) (2.78) (6.20) (5.74) (9.43) (6.40) (6.17) (5.9)
Cash, $m
Cash, $m Operating cash flow (18) (21) (21) (44) (67) (96) (127) (168) (219) (111) (91) +22.1%
Capex 0 — 0 0 0 0 0 (1) (1) 0 (1) +2.0%
Free cash flow (18) (21) (21) (44) (67) (96) (128) (169) (219) (111) (91) +22.1%
Balance, $m
Balance, $m Working capital 108 89 159 113 169 142 104 233 403 409 394 +15.9%
Net debt (115) (95) (164) (137) (172) (133) (122) (253) (290) (240) (168) +8.5%
Shareholders’ equity 122 104 178 135 211 126 80 248 280 226 227 +7.0%
Returns, %
Returns, % ROA (21.17) (23.21) (18.28) (39.08) (34.67) (46.75) (68.12) (62.99) (35.34) (14.34) (8.74) +6.8 pt
ROIC (263.57) (206.77) (137.01) 0.00 (122.54) 0.00 0.00 0.00 0.00 0.00 (34.12) +263.6 pt
ROE (22.33) (24.69) (19.19) (43.82) (43.70) (68.84) (137.49) (112.29) (66.09) (32.99) (20.12) (10.7) pt
People
People Employees 18 18 18 46 55 72 107 141 229 258 — +34.4%
Revenue/emp, $m 0.34 0.06 0.06 0.01 0.00 0.02 0.01 0.00 0.34 0.71 — +8.5%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 6 Nov 2026

Geron Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FDMT 4D Molecular Therapeutics, Inc. $621.5M — (loss-making) — (loss-making) +25,106.67% (above 0%: growing) n/m −61.28% (below 0%: shrinking) 100.00% (2,037.16%) Compare
DBVT DBV Technologies S.A. $615.8M — (loss-making) — −42.86% (below 0%: shrinking) n/m −64.93% (below 0%: shrinking) 100.00% (4,043.75%) Compare
CADL Candel Therapeutics, Inc. $615.2M — (loss-making) — (loss-making) 0.00% n/m −93.35% (below 0%: shrinking) 0.00% 0.00% Compare
HELP Cybin Inc. $613.0M — (loss-making) — (loss-making) — n/m −25.60% (below 0%: shrinking) 0.00% 0.00% Compare
GERN Geron Corporation $610.4M — (loss-making) — (loss-making) +27.45% (above 0%: growing) n/m +176.13% (above 0%: growing) 89.95% 9.63%
DSGN Design Therapeutics, Inc. $605.2M — (loss-making) — (loss-making) — n/m −7.00% (below 0%: shrinking) 0.00% 0.00% Compare
KURA Kura Oncology, Inc. $604.9M — (loss-making) — (loss-making) +36.54% (above 0%: growing) n/m −109.05% (below 0%: shrinking) 98.84% (349.77%) Compare
AVBP ArriVent BioPharma, Inc. $603.0M — (loss-making) — — n/m −51.51% (below 0%: shrinking) — 0.00% Compare
IMMX Immix Biopharma, Inc. $596.9M — (loss-making) — — n/m −116.22% (below 0%: shrinking) — 0.00% Compare
Median of peers $609.1M — — +18.27% — −63.10% 49.42% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 7 April 2026

Ownership

Directors and executive officers, together 1.71%
RA Capital Management, L.P. 9.98%
Soleus Capital Master Fund, L.P. 5.15%
Deep Track Capital, LP 5.07%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Geron Corporation (GERN) Latest News

5 Nov

Impact 3 · · The Motley Fool

4 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · Moby
Impact 3 · · MarketBeat
Impact 3 · · GlobeNewswire

30 Oct

Impact 3 · · clinicaltrialsarena.com

28 Oct

Impact 4 · · Investing.com
Impact 4 · · GlobeNewswire
Impact 3 · · MT Newswires

12 Oct

Impact 3 · · GlobeNewswire

16 Sep

Impact 4 · · MarketBeat

13 Sep

Impact 4 · · MarketBeat

9 Aug

Impact 4 ·
Impact 3 ·

6 Aug

Impact 3 · · The Motley Fool transcript

5 Aug

Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

12 May

Impact 3 · · GlobeNewswire

8 May

Impact 4 ·
Impact 4 · · Simply Wall St.

7 May

Impact 3 · · Moby

6 May

Impact 4 · · MarketBeat
Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

13 Apr

Impact 4 · · MarketBeat

29 Mar

Impact 4 · · Simply Wall St.

17 Mar

Impact 4 · · MarketBeat
stockrow.com/GERN · Data as of Nov 6, 2026 · For information only; not investment advice. · © 2026 stockrow.com